# Avantor account plan

> Avantor supplies lab consumables, chemicals and bioprocessing materials to 300,000+ customer locations; FY2025 net sales $6,552.2 million.

## At a glance

Avantor sells products and services to biopharma and healthcare, education and government, and advanced technologies and applied materials customers, through the VWR distribution channel and its own manufactured brands (J.T. Baker, Masterflex, NuSil). It serves more than 300,000 customer locations in approximately 180 countries and had approximately 13,500 employees at December 31, 2025, about 4,800 of them in the U.S. FY2025 net sales were $6,552.2 million (down 3.4%, organic -2.8%), with a net loss of $530.2 million after a $785.0 million goodwill impairment and Adjusted EBITDA of $1,069.4 million (16.3% margin). More than 85% of net sales are recurring. The company has been listed on the NYSE since May 2019 and is led by CEO Emmanuel Ligner since August 2025.

## Business units

- **VWR Distribution & Services** ($3,624.3 million of nine-month 2026 net sales; about 70% of revenues per management): Distributes lab consumables, chemicals and equipment through the VWR channel and provides onsite lab services and specialty procurement to biopharma, education, industrial and technology customers. Q3 2026 net sales were $1,233.8 million, organic +5.8%, driven by specialty procurement volumes, consumables and lab chemicals, but Adjusted Operating Income fell 9.5% to $119.4 million on product mix and higher SG&A. Its goodwill is at risk: fair value exceeded carrying value by only about 5.5% at March 31, 2026.
- **Bioscience & Medtech Products** ($1,347.7 million of nine-month 2026 net sales): Manufactures fluid handling single-use systems, process chemicals and excipients, NuSil medical and aerospace grade silicones, and research and specialty chemicals including semiconductor formulations. Q3 2026 net sales were $464.5 million, organic +3.6%, led by NuSil and Process Chemicals, with Adjusted Operating Income up 3.4% to $123.4 million. Book-to-bill has been positive for a third quarter in a row.

## Strategic priorities

- **Avantor Revival turnaround**: Launched in October 2025 with five pillars: go-to-market and brand architecture, manufacturing and supply chain investment, portfolio scrutiny, net cost savings and simplification, and talent and accountability. The stated goal is a return to growth, which Q3 2026 delivered with organic growth of 5.2%.
- **Commercial excellence in VWR**: Management estimates approximately half of VWR growth in Q3 2026 came from commercial initiatives: large contract renewals, small and mid-sized accounts, and e-commerce after the vwr.com relaunch.
- **AI and digital sales tools**: The VWR Internal Sales Assistant (ISA) combines customer, sales and product data to prepare meetings, generate leads and prioritise opportunities; an AI cross-reference tool suggests substitute products. Approximately 80% of 2025 transactions already came through digital channels.
- **Pricing to offset inflation**: Pricing in 2026 is between 1 and 2%, below inflation; new pricing leaders and tools are in place, and year-end large contracts are the opportunity to raise prices for following years.
- **Deleveraging**: Adjusted net leverage was 3.1x after Q3 2026, with a target below 3x by year end; net debt was reduced by $173 million to $3.235 billion in the quarter.
- **Long-term framework at Investor Day**: An Investor Day on December 8 is to present segments, strategy, capital allocation and a long-term financial framework; 2027 guidance is deferred to the Q4 call in February.

## Latest results

In Q3 2026 (quarter ended September 30, 2026) net sales were $1,698.3 million, up 4.6% (organic +5.2%), Avantor's return to year-over-year growth. Net income was $203.4 million against a $711.8 million loss in Q3 2025, which carried the goodwill impairment. Adjusted EBITDA was $256.9 million, a 15.1% margin versus 16.5%, as gross margin fell 90 bps to 31.5% on product mix and inflation. For the nine months, net sales were $4,972.0 million (organic +0.3%) and Adjusted Operating Income fell 12.2% to $643.3 million. 2026 guidance was raised to organic growth of 0.75% to 1.25%, adjusted EPS of $0.81 to $0.83 and free cash flow of $525 million to $550 million.

## Investments and deals

- **Manufacturing and supply chain upgrades**: Revival invests in plants, S&OP and on-time delivery in bioprocessing chemicals; a long-term strategy aims to manufacture in Asia, Europe and the US for security of supply. Electronic batch records were introduced at two sites. FY2025 capex was $128.8 million.
- **E-commerce and leadership hires**: vwr.com was relaunched at the end of Q1 / early Q2 2026, a Chief Digital Officer was hired, and a new CIO (Mikey Santiago, from Danaher) and CFO (Todd Garner) completed the executive team; about 65% of N-2 managers were refreshed.
- **Share buyback**: A $500.0 million buyback was authorised in October 2025; $75.0 million was used in November 2025 and $425.0 million remains, with no repurchases in Q3 2026.
- **Refinancing**: In Q4 2025, €400.0 million and €550.0 million term loans replaced earlier term loans and notes, and the revolver was raised to $1,400.0 million. Total debt was $3,946.3 million at December 31, 2025.
- **Cost transformation and portfolio review**: The cost transformation programme targeted approximately $400 million of run-rate gross savings by the end of 2027 and concluded in 2025; Clinical Services was sold in October 2024, and each business is now held to growth, profitability and return targets.

## Challenges and risks

- **Goodwill impairment risk on VWR Distribution**: After a $785.0 million impairment in Q3 2025, the unit's fair value exceeded carrying value by only about 5.5% at March 31, 2026, with approximately $2,800.0 million of goodwill allocated to it.
- **Margin pressure**: Q3 2026 Adjusted EBITDA margin fell to 15.1% from 16.5%; VWR adjusted operating margin was 9.7%, hit by mix, inflation and growth investment, and pricing of 1 to 2% trails inflation.
- **Research funding and Europe**: The 10-K names reductions in research budgets and NIH-type government funding as a key risk; academic and government sales fell double digits in Q3 2025, and Europe is lagging on energy costs and government funding pressure.
- **Competition and plant reliability**: Avantor operates in a fragmented, highly competitive market and lost some large lab services accounts; in 2025, plant downtime, raw material availability and equipment uptime limited bioprocessing chemical shipments.
- **Indebtedness and tariffs**: Gross principal of $3,967.9 million, tariffs and trade policy, and FX exposure to the Euro are listed among the key risks.

## What leadership says

> "We estimate that approximately half of VWR growth in Q3 was driven by our commercial initiatives" — Emmanuel Ligner, President and Chief Executive Officer, Avantor Q3 2026 earnings call, 2026-10-28

> "our number one objective is pricing to offset inflation right now" — Emmanuel Ligner, President and Chief Executive Officer, Avantor Q3 2026 earnings call, 2026-10-28

> "we are going to scrutinize whether we are the right owner for them" — Emmanuel Ligner, President and Chief Executive Officer, Avantor Q3 2025 earnings call (Avantor Revival launch), 2025-10-29

> "accountability will be my North Star." — Emmanuel Ligner, President and Chief Executive Officer, Avantor Q3 2025 earnings call (Avantor Revival launch), 2025-10-29


## Where a supplier can help

- **Sales productivity and AI tooling for VWR**: Tied to the commercial excellence priority and the VWR Internal Sales Assistant: suppliers of sales data, lead generation and account-prioritisation tools can help extend the commercial initiatives that drove about half of VWR growth.
- **E-commerce and digital channel**: Tied to the vwr.com relaunch and the new Chief Digital Officer: platform, search, recommendation and content providers fit a channel that already carries most transactions.
- **Plant reliability and supply chain**: Tied to the manufacturing and supply chain investment pillar and the 2025 shipment limits in bioprocessing chemicals: maintenance, equipment uptime, S&OP and multi-region sourcing offers address a stated constraint.
- **Pricing and margin tools**: Tied to the margin pressure challenge and the pricing priority: pricing analytics and cost-to-serve tools help a business whose pricing trails inflation.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Avantor, Inc. Annual Report on Form 10-K for fiscal year 2025](https://www.sec.gov/Archives/edgar/data/1722482/000162828026007118/avtr-20251231.htm)

Annual report · 2026-02-11

- Avantor is a global provider of products and services to biopharma & healthcare, education & government, and advanced technologies & applied materials customers, serving more than 300,000 customer locations in approximately 180 countries with approximately 13,500 employees (4,800 in the U.S.).
- Two go-to-market routes: the VWR channel (distribution of consumables and equipment to laboratories, with a private label used by more than 5,000 suppliers) and manufactured proprietary products (J.T. Baker high-purity chemicals, Masterflex fluid handling, NuSil implant-grade silicones).
- FY2025 net sales were $6,552.2 million, down 3.4% (organic decline 2.8%); net loss of $530.2 million after a $785.0 million goodwill impairment on the Distribution reporting unit; Adjusted EBITDA $1,069.4 million (16.3% margin).
- Segments in 2025: Laboratory Solutions $4,399.7 million of net sales (organic -3.2%, hit by weaker Total Science Solutions demand and the Clinical Services divestiture) and Bioscience Production $2,152.5 million (organic -1.8%).
- More than 85% of net sales are recurring; approximately 80% of transactions came through digital channels; about 45% of 2025 sales came from customers of 15 years or more, and no end customer exceeds 5% of sales.
- Cost transformation expanded to approximately $400 million of run-rate gross savings by the end of 2027 (from approximately $300 million by end of 2026).
- Balance sheet: total debt of $3,946.3 million, refinanced in Q4 2025 with €400.0 million and €550.0 million term loans; revolver raised to $1,400.0 million; a $500.0 million buyback authorized in October 2025 ($75.0 million used).
- New leadership: Emmanuel Ligner (ex-Cytiva/Danaher, Cerba HealthCare) CEO since August 2025, Mary Blenn COO since November 2025, Corey Walker President of Laboratory Solutions since April 2025.
- Key risks: reductions in customers' research budgets and NIH-type government funding, competition, tariffs and trade policy, FX (Euro), integration and supply risks, significant indebtedness, and shareholder activism.

### [Avantor, Inc. Quarterly Report on Form 10-Q for Q3 2026 (quarter ended September 30, 2026)](https://www.sec.gov/Archives/edgar/data/1722482/000162828026067751/avtr-20260930.htm)

Interim report · 2026-10-28

- Q3 2026 net sales were $1,698.3 million, up 4.6% (organic +5.2%), Avantor's return to year-over-year growth.
- New segments since January 1, 2026: VWR Distribution & Services ($1,233.8 million in Q3, organic +5.8%) and Bioscience & Medtech Products ($464.5 million, organic +3.6%).
- Net income $203.4 million vs a $711.8 million loss in Q3 2025 (which carried the $785.0 million goodwill impairment); Q3 included an income tax benefit from an internal reorganization.
- Adjusted EBITDA $256.9 million (15.1% margin vs 16.5%); Adjusted Operating Income $227.6 million (13.4% vs 14.6%), with VWR margin hurt by product mix and higher SG&A.
- Nine months: net sales $4,972.0 million (organic +0.3%); Adjusted Operating Income down 12.2% to $643.3 million.
- VWR Distribution reporting unit at risk of goodwill impairment: its fair value exceeded carrying value by only about 5.5% at March 31, 2026.
- Liquidity of $1,844.2 million; $425.0 million left on the buyback, with no repurchases in the quarter.

### [Avantor Q3 2026 earnings call transcript](https://www.webull.com/news/15826018701411328)

Executive talk · Emmanuel Ligner, President and Chief Executive Officer · 2026-10-28

- Ligner calls Q3 2026 "an important milestone on our Revival journey": revenue of $1,698,000,000, organic growth of 5.2%, ahead of expectations; 2026 guidance raised to 0.75% to 1.25% organic growth, adjusted EPS $0.81 to $0.83 and free cash flow $525 million to $550 million.
- VWR organic growth accelerated to 5.8%; management estimates "approximately half of VWR growth in Q3 was driven by our commercial initiatives" (large contract renewals, small and mid-sized accounts, e-commerce).
- BMP grew 3.6% organically: process chemicals up high single digits, NuSil up low teens, with positive book-to-bill for a third quarter; a key NuSil customer contract was renewed to 2031.
- End markets are "the most constructive we have seen in several years": large pharma and biotech strong, green shoots in North American higher education and early-stage biotech, Europe lagging.
- Revival investment priorities: AI (the VWR Internal Sales Assistant, ISA), supply chain, and the e-commerce platform after the vwr.com relaunch; a new CIO (Mikey Santiago, from Danaher) completes the leadership team, and about 65% of N-2 managers have been refreshed.
- Pricing in 2026 is "between 1 and 2%", below inflation; adjusted net leverage of 3.1x, targeted below 3x by year-end.
- An Investor Day on December 8 will give a long-term financial framework.

### [Avantor Q3 2025 earnings call transcript (Avantor Revival launch)](https://www.fool.com/earnings/call-transcripts/2026/04/21/avantor-avtr-q3-2025-earnings-transcript/)

Executive talk · Emmanuel Ligner, President and Chief Executive Officer · 2025-10-29

- Ligner's first earnings call, about 10 weeks after joining from Cytiva/Danaher: the problems are "generally self-inflicted" and "fixable with determination, focus and time".
- Q3 2025: revenue $1.62 billion, down 5% organically; $785 million goodwill impairment on the lab distribution business; adjusted EBITDA margin 16.5%; free cash flow $172 million.
- He launched "Avantor Revival" with five pillars: go-to-market and brand architecture (more prominence for VWR, J.T.Baker, Masterflex, NuSil), investment in manufacturing and supply chain, portfolio scrutiny, net cost savings and simplification, and talent and accountability.
- New roles: a Chief Operating Officer, a head of quality and regulatory reporting to the CEO, and a Chief Digital Officer for e-commerce.
- A $500 million share buyback was authorized because the share price "does not reflect the long-term value of our platform".
- Laboratory Solutions has lost no key account renewal since Corey Walker joined and won about $100 million of business at 2 top-15 pharma customers, phasing in from 2026; bioprocessing chemicals order intake is up high single digits, but plant reliability limits shipments.
- Portfolio review: if a business cannot meet growth, profitability and return targets, "we are going to scrutinize whether we are the right owner for them".

## Questions about Avantor

### What does Avantor do?

Avantor supplies lab consumables, chemicals, equipment and services through its VWR channel, and manufactures bioprocessing materials, high-purity chemicals and NuSil silicones for biopharma, healthcare, education and advanced technology customers.

### What is Avantor's revenue?

FY2025 net sales were $6,552.2 million, down 3.4%. Q3 2026 net sales were $1,698.3 million, up 4.6%.

### How many employees does Avantor have?

Approximately 13,500 at December 31, 2025, about 4,800 of them in the U.S.

### Who leads Avantor?

Emmanuel Ligner has been President and CEO since August 2025; Mary Blenn is COO and Todd Garner joined as CFO in September 2026.

### What is Avantor's strategy?

The Avantor Revival programme focuses on go-to-market and brands, manufacturing and supply chain, portfolio scrutiny, cost simplification and talent, with the goal of returning to profitable growth.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
